Abstract
We conducted a case-control study to determine the attributable direct costs of multidrug-resistant Acinetobacter baumannii (MDRAB) in the burn unit of a public teaching hospital. The mean total hospital cost of patients who acquired MDRAB was 98,575 dollars higher than that of control patients who had identical burn severity of illness indices ( P <.01). These data should help infection control practitioners and others determine the cost-effectiveness of specific interventions designed to control this emerging nosocomial pathogen.
MeSH terms
-
Acinetobacter Infections / diagnosis
-
Acinetobacter Infections / drug therapy*
-
Acinetobacter Infections / economics*
-
Acinetobacter Infections / epidemiology
-
Acinetobacter baumannii / isolation & purification*
-
Adult
-
Aged
-
Anti-Bacterial Agents / economics*
-
Anti-Bacterial Agents / therapeutic use
-
Burn Units
-
Case-Control Studies
-
Cross Infection / economics
-
Cross Infection / epidemiology
-
Cross Infection / microbiology
-
Drug Resistance, Multiple, Bacterial
-
Female
-
Follow-Up Studies
-
Hospital Costs*
-
Hospitals, Teaching
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Probability
-
Reference Values
-
Risk Assessment
-
United States